Little Green Pharma Ltd

ASX:LGP Stock Report

Market Cap: AU$39.4m

Little Green Pharma Management

Management criteria checks 1/4

Little Green Pharma's CEO is Paul Long, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is A$734.09K, comprised of 25.3% salary and 74.7% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth A$315.41K. The average tenure of the management team and the board of directors is 1.6 years and 6.1 years respectively.

Key information

Paul Long

Chief executive officer

AU$734.1k

Total compensation

CEO salary percentage25.3%
CEO tenure1.3yrs
CEO ownership0.8%
Management average tenure1.6yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Improved Revenues Required Before Little Green Pharma Ltd (ASX:LGP) Shares Find Their Feet

Nov 19
Improved Revenues Required Before Little Green Pharma Ltd (ASX:LGP) Shares Find Their Feet

The Market Doesn't Like What It Sees From Little Green Pharma Ltd's (ASX:LGP) Revenues Yet As Shares Tumble 27%

Jun 30
The Market Doesn't Like What It Sees From Little Green Pharma Ltd's (ASX:LGP) Revenues Yet As Shares Tumble 27%

Estimating The Fair Value Of Little Green Pharma Ltd (ASX:LGP)

Jun 17
Estimating The Fair Value Of Little Green Pharma Ltd (ASX:LGP)

Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?

Mar 05
Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?

Not Many Are Piling Into Little Green Pharma Ltd (ASX:LGP) Just Yet

Nov 01
Not Many Are Piling Into Little Green Pharma Ltd (ASX:LGP) Just Yet

A Look At The Intrinsic Value Of Little Green Pharma Ltd (ASX:LGP)

May 08
A Look At The Intrinsic Value Of Little Green Pharma Ltd (ASX:LGP)

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Sep 06
Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

Feb 11
What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?

CEO Compensation Analysis

How has Paul Long's remuneration changed compared to Little Green Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-AU$9m

Jun 30 2024n/an/a

-AU$9m

Mar 31 2024AU$734kAU$186k

-AU$8m

Compensation vs Market: Paul's total compensation ($USD458.37K) is above average for companies of similar size in the Australian market ($USD291.23K).

Compensation vs Earnings: Insufficient data to compare Paul's compensation with company performance.

CEO

Paul Long

1.3yrs

Tenure

AU$734,086

Compensation

Mr. Paul Long serves as Executive Chair at Reset Mind Sciences Limited since February 2024. He serves as a Director of WellteQ Pte. Ltd.As a WellteQ co-founder, Mr. Long is an active contributor to the vi...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Long
Chief Executive Officer1.3yrsAU$734.09k0.80%
A$ 315.4k
Angus Caithness
CFO & Executive Director1.9yrsAU$986.03k3.79%
A$ 1.5m
Fleta Solomon
Executive Director1.3yrsAU$856.56k7.22%
A$ 2.8m
Alistair Warren
General Counsel & Company Secretary4.4yrsno datano data

1.6yrs

Average Tenure

Experienced Management: LGP's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Angus Caithness
CFO & Executive Director6.8yrsAU$986.03k3.79%
A$ 1.5m
Fleta Solomon
Executive Director7.6yrsAU$856.56k7.22%
A$ 2.8m
Neale Fong
Independent Non Executive Director6.1yrsAU$84.92k0.51%
A$ 201.6k
Michael Lynch-Bell
Independent Non Executive Chairman6.1yrsAU$169.52k0.58%
A$ 228.6k
Joe Kosterich
Medical Advisorno datano datano data
Beatriz Vicen Banzo
Independent Non-Executive Director2.4yrsAU$90.15k0.017%
A$ 6.5k

6.1yrs

Average Tenure

Experienced Board: LGP's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 17:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Little Green Pharma Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cameron BellCanaccord Genuity